Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950
Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research

INDRAPRASTHA GAS
Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

image
Business Standard
177 22
Business Standard

Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

SI Team  |  Mumbai 



DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950


Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research

INDRAPRASTHA GAS
Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

RECOMMENDED FOR YOU

Analysts' corner

Dr Reddy's Labs & Indraprastha Gas

Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

DR REDDY’S LABS
Reco price: Rs 1,709;
Target price: Rs 1,950
Dr Reddy’s (DRRD) has filed an abbreviated new drug application for singulair granules oral formulation, used for treatment of asthma in children. Innovator Merck has sued DRRD for infringement of a patent on this, which expires in October 2022. This product has $80 million annual sales in the US. DRRD can launch earliest in September 14, after expiry of a 30-month stay on generic launch. Mylan and Teva could be the first to file on this product. Overweight.

HSBC Global Research

INDRAPRASTHA GAS
Reco price: Rs 346;
Target price: Rs 426
The Petroleum and Natural Gas Regulatory Board (PNGRB) has issued an order on network rates and compression charge for (IGL);. Against IGL’s proposed Rs 7.8/scm of network rate and compression charge, the PNGRB has allowed a mere Rs 3.1/scm, a decline of Rs 4.7/scm. Even after allowing for a marketing margin over and above this (the quantum of which, however, is uncertain), the order comes as a significant negative surprise, leading to a potential downside of 45-65 per cent to Citigroup’s Ebitda. Under this scenario, IGL will struggle to make even normative returns on the capital it has invested in the business. Maintain buy.

Citigroup

image
Business Standard
177 22

LIVE MARKET

BSE

  ( %)

NSE

  ( %)

More News

  • Rating agency shares soar on corporate bond Rating agency shares soar on corporate bond boost
  • Moody’s RBI norms on corporate bonds credit positive, says Moody's

STOCK WATCH

Company Price() Chg(%)
Trident 56.00 12.45
VST Inds. 2296.20 10.12
GRUH Finance 345.20 9.33
J B Chem & Pharm 336.60 7.90
Century Textiles 709.85 5.92
> More on BSE Gainers
Company Price() Chg(%)
Trident 56.45 13.13
Future Lifestyle 137.65 10.92
GRUH Finance 346.05 9.46
VST Inds. 2284.90 9.22
J B Chem & Pharm 336.50 7.71
> More on NSE Gainers
Company Price() Chg(%)
Welspun India 49.70 -8.64
Shilpa Medicare 553.00 -7.82
Piramal Enterp. 1851.10 -5.41
Jaypee Infratec. 9.21 -4.76
Avanti Feeds 534.10 -4.20
> More on BSE Gainers
Company Price() Chg(%)
Welspun India 49.40 -8.60
Shilpa Medicare 551.70 -7.87
IDBI Bank 70.45 -6.38
Jaypee Infratec. 9.10 -5.70
Piramal Enterp. 1847.10 -5.48
> More on NSE Gainers
Widgets Magazine
Widgets Magazine
Widgets Magazine

Derivatives

Index
Instrument Type
Expiry Date
Option Type
Strike Price

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard